| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Centre Oscar Lambret, Rue F. Combemale, BP 307-59020 Lille Cèdex [J. B., J. P. P., A. D.], and Centre d'Etude et de Recherche sur l'Informatique Médicale, Faculté de Médecine, Place de Verdun, 59037 Lille [R. B.], France
Overall survival (OS) and relapse free survival (RFS) were studied in 297 patients according to the presence of insulin-like growth factor 1 receptors (IGF1-R). All the patients were surgically treated for locoregional disease in the same institution from January 1986. The median duration of follow-up was 40 months. RFS was better in patients with IGF1-R in their tumors as assessed by actuarial survival (P = 0.014) as well as Cox analysis (P = 0.016). OS was better in IGF1-R positive tumors studied by actuarial (P = 0.007) as well as Cox analysis (P = 0.010). By Cox analysis the other prognostic factors on RFS were estrogen receptor (P = 0.002), progesterone receptor (P = 0.002), axillary node metastases (P = 0.032), histoprognostic grading (GHP) according to the standard of Scarff and Bloom (P = 0.004), and tumor diameter (P = 0.019). The other prognostic factors on OS (Cox analysis) were estrogen receptor (P = 0.001), axillary node metastases (P = 0.010), GHP (P = 0.009), progesterone receptor (P = 0.012), and tumor diameter (P = 0.007). When combining IGF1-R, GHP, and axillary node metastases, it appeared that IGF1-R, GHP, and axillary node metastases had independent prognostic significance. In this prospective study IGF1-R had a prognostic significance on RFS as well as on OS studied by actuarial as well as Cox analysis.
1 This work was supported by the Ligue Nationale Contre le Cancer (Paris), Ligue du Nord Contre le Cancer (Lille) and Association pour la Recherche sur le Cancer (Villejuif).
Received 7/12/90. Accepted 7/20/90.
This article has been cited by other articles:
![]() |
J. Matsubara, Y. Yamada, Y. Hirashima, D. Takahari, N. T. Okita, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, and T. Shimoda Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3022 - 3029. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Revillion, M. Charlier, V. Lhotellier, L. Hornez, S. Giard, M.-C. Baranzelli, J. Djiane, and J.-P. Peyrat Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2088 - 2094. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakamura, S. Miyamoto, H. Maeda, S.-c. Zhang, T. Sangai, G. Ishii, T. Hasebe, Y. Endoh, N. Saito, M. Asaka, et al. Low Levels of Insulin-Like Growth Factor Type 1 Receptor Expression at Cancer Cell Membrane Predict Liver Metastasis in Dukes' C Human Colorectal Cancers Clin. Cancer Res., December 15, 2004; 10(24): 8434 - 8441. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Goodwin, M. Ennis, K. I. Pritchard, M. E. Trudeau, J. Koo, Y. Madarnas, W. Hartwick, B. Hoffman, and N. Hood Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study J. Clin. Oncol., January 1, 2002; 20(1): 42 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Descamps, V. Pawlowski, F. Revillion, L. Hornez, M. Hebbar, B. Boilly, H. Hondermarck, and J.-P. Peyrat Expression of Nerve Growth Factor Receptors and Their Prognostic Value in Human Breast Cancer Cancer Res., June 1, 2001; 61(11): 4337 - 4340. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Molloy, F. E. B. May, and B. R. Westley Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line J. Biol. Chem., April 21, 2000; 275(17): 12565 - 12571. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hebbar, F. Revillion, M.-M. Louchez, C. Fournier, J. Bonneterre, and J.-P. Peyrat Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients Clin. Cancer Res., June 1, 1999; 5(6): 1427 - 1433. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |